DXRX Stock Overview
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide.
Diaceutics PLC Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.76|
|52 Week High||UK£1.22|
|52 Week Low||UK£0.74|
|1 Month Change||-4.43%|
|3 Month Change||-17.94%|
|1 Year Change||-25.25%|
|3 Year Change||-20.53%|
|5 Year Change||n/a|
|Change since IPO||-20.94%|
Recent News & Updates
Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)Jul 24
Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?Feb 04
Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings PotentialDec 31
Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?Nov 27
|DXRX||GB Life Sciences||GB Market|
Return vs Industry: DXRX exceeded the UK Life Sciences industry which returned -52.8% over the past year.
Return vs Market: DXRX underperformed the UK Market which returned -6% over the past year.
|DXRX Average Weekly Movement||2.3%|
|Life Sciences Industry Average Movement||8.4%|
|Market Average Movement||5.8%|
|10% most volatile stocks in GB Market||11.1%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: DXRX is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: DXRX's weekly volatility (2%) has been stable over the past year.
About the Company
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks.
Diaceutics PLC Fundamentals Summary
|DXRX fundamental statistics|
Is DXRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DXRX income statement (TTM)|
|Cost of Revenue||UK£4.05m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.0015|
|Net Profit Margin||0.83%|
How did DXRX perform over the long term?See historical performance and comparison